A 16-year clinical experience with intermittent androgen deprivation for prostate cancer: Oncological results

World Journal of Urology

Volumn 27, Issue 5, 2009, Pages 627-635

  Prapotnich, Dominique ^a   Cathelineau, Xavier ^a   Rozet, François ^a   Barret, Eric ^a   Mombet, Annick ^a   Cathala, Nathalie ^a   Sanchez Salas, Rafael E ^a   Vallancien, Guy ^a  

^a INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Androgen blockade; Castration; Intermittent therapy; Neoplastic metastasis; Prostate cancer

Indexed keywords

ANDROGEN RECEPTOR; ANILIDE; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BICALUTAMIDE; GONADORELIN; GOSERELIN; NITRILE; TOLUENESULFONIC ACID DERIVATIVE;

AGED; ARTICLE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG POTENTIATION; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; NITRILES; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TIME FACTORS; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 70349485852     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0393-1     Document Type: Article

References (36)

1. Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
2. Prostate Cancer Trialists' Collaborative Group (1995) Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3,283 deaths in 5,710 patients. Lancet 346:265-269
3. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA (2000) Complete androgen blockade for prostate cancer: What went wrong? J Urol 164:3-9. doi: 10.1016/S0022-5347(05)67436-8
4. Daniell HW (2001) Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 58(2 Suppl 1):101-107. doi: 10.1016/ S0090-4295(01)01251-1
5. Grossfeld GD, Li YP, Lubeck DP, Carroll PR (2002) Patterns of failure after primary localtherapy for prostate cancer and rationale for secondary therapy. Urology 60:57-62. doi: 10.1016/S0090-4295(02)01574-1
6. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT (2006) Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 98(16):1134-1141
7. Cooperberg MR, Cowan J, Broering JM, Carroll PR (2008) High-risk prostate cancer in the United States, 1990-2007. World J Urol 26(3):211-218. doi: 10.1007/s00345-008-0250-7
8. The Medical Research Council Prostate Cancer Working Party Investigators Group (1997) Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 79:235-246
9. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Toreccilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 360(9327):103-106. doi: 10.1016/ S0140-6736(02)09408-4
10. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781-1788. doi: 10.1056/ NEJM199912093412401
11. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. JCO 17(11):3461-3467
12. Clarke NW (2006) Management of the spectrum of hormone refractory prostate cancer. Eur Urol 50(3):428-439. doi: 10.1016/ j.eururo.2006.05.017
13. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Goldenberg SL, Lange PH, Sullivan LD (1996) Intermittent androgen suppression delays progression to androgen-independant regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol 58:139-146. doi: 10.1016/0960-0760(96)00018-0
14. Buhler KR, Santucci RA, Royai RA, Whitney SC, Vessela RL, Lange PH, Ellis WJ (2000) Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. Prostate 43(1):63-70. doi: 10.1002/ (SICI)1097-0045(20000401)43:1<63::AID-PROS9>3.0.CO;2-D
15. Akakura K, Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, Tenniswood M, Fox K (1996) Effects of intermittent androgen suppression on the stem cell composition and the expression of TPRM-2 (clusterin) gene in the shionogi carcinoma. J Steroid Biochem Mol Biol 59:501-511. doi: 10.1016/S0960-0760(96)00132-X
16. Tunn U (2007) The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: Putting IAD under the spotlight. BJU Int 99:19-22. doi: 10.1111/j.1464-410X.2007.06596.x
17. Janknegt RA, Abbou CC, Bartoletti R, Berstein-Hahn L, Bracken B, Brisset JM, Calais Da Silva F, Chisholm G, Crawford ED, Debruyne FMJ, Dijkman GD, Frick J, Goedhals L, Knönagel H, Venner PM (1993) Orchidectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind trial. J Urol 149:77-83
18. Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, Doré B, The members of the Association for Research in Urological Oncology (2008) Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: A randomised study. Eur Urol 54(2):382-391. doi: 10.1016/j.eururo.2008.02.024
19. Crook JM, Szumacher E, Malone S, Huan S, Segal R (1999) Intermittent androgen suppression in the management of prostate cancer. Urology 53:530-534. doi: 10.1016/S0090-4295(98)00547-0
20. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K (1995) Intermittent androgen suppression in the treatment of prostate cancer: A preliminary report. Urology 45:839-844. doi: 10.1016/ S0090-4295(99)80092-2
21. Higano CS, Ellis W, Russel K, Lange PH (1996) Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: A pilot study. Urology 48:800-804. doi: 10.1016/S0090-4295(96)00381-0
22. Sciarra A, Di Chiro C, Di silverio F (2000) Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol 18(6):392-400. doi: 10.1007/s003450000155
23. Theyer G, Hamilton G (1998) Current status of intermittent androgen suppression in the treatment of prostate cancer. Urology 52:353-359. doi: 10.1016/S0090-4295(98)00251-9
24. Therneau TM, Grambsch PM (2000) Modeling survival data: Extending the Cox model. Causes of mortality related or not to prostate cancer were analyzed using a competing risk framework by computing cumulative incidence curves. Springer, New York. ISBN: 0-387-98784-3
25. Horwich A, Huddart RA, Gadd J, Boyd PJ, Hetherington JW, Whelan P, Dearnaley DP (1998) A pilot study of intermittent androgen deprivation in advanced prostate cancer. BJU 81:96-99. doi: 10.1046/ j.1464-410x.1998.00521.x
26. Klotz LH, Herr HW, Morse MJ, Whitmore WF (1986) Intermittent endocrine therapy for advanced prostate cancer. Cancer 58:2546-2550. doi: 10.1002/ 1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N
27. Kurek R, Renneberg H, Lübben G, Kienle E, Tunn UW (1999) Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer. Eur Urol 35:27-31. doi: 10.1159/000052304
28. Grossfeld GD, Chaudary UB, Reese DM, Carroll PR, Small EJ (2001) Intermittent androgen deprivation: Update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology 58(2):240-245. doi: 10.1016/S0090-4295(01)01114-1
29. Zerbib M, Conquy S, Gerbaud PF, Missirliu A, Thioun N, Flam T, Debre B (1998) Efficacy and effect on quality of life (QOL) of intermittent androgen deprivation for prostate cancer treatment. Eur Urol 33(suppl 1):A354
30. Prapotnich D, Fizazi K, Escudier B, Mombet A, Cathala N, Vallancien G (2003) A 10-year clinical experience with intermittent hormonal therapy for prostate cancer. Eur Urol 43(3):233-240. doi: 10.1016/ S0302-2838(03)00004-6
31. Bhandari MS, Crook J, Hussain M (2005) Should intermittent androgen deprivation be used in routine clinical practice? JCO 23(32):8212-8218
32. Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R (2007) Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 178(4Pt 1):1290-1295. doi: 10.1016/ j.juro.2007.05.129
33. Alcaraz A, Teillac P (2006) Hormone therapy for prostate cancer: guidelines versus clinical practice. Eur Urol Suppl 5:362-368. doi: 10.1016/j.eursup.2006.01.001
34. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L et al (2002) Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer 1(3):163-171
35. Miller K, Steiner U, Lingnau A, Keilholz U, Witzsch U, Haider A, Watcher U, Rüssel C, Altwein J (2007) Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. JCO (ASCO meeting proceedings part I.); 25 (No. 18S June 20 supplement): 5015
36. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K (2007) The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178(4 Pt 1):1282-1288. doi: 10.1016/j.juro.2007.05.138